This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Magistrate judge recommends maintaining antitrust case against Ranbaxy, Sun Pharmaceutical

( June 16, 2016, 22:31 GMT | Official Statement) -- Mlex Summary: US Magistrate Judge M. Page Kelley has recommended denying Ranbaxy and Sun Pharmaceutical Industries’ motion to dismiss Meijer's claims that they conspired to delay the market entry of several generic drugs. Kelley said that Sherman Act claims aren't precluded under the Food, Drug and Cosmetic Act, and Meijer sufficiently alleged that Ranbaxy filed meritless applications with the US Food and Drug Administration in order to keep out generic competition. However, Kelley recommended dismissing claims against Ranbaxy USA and Ranbaxy Laboratories, who are no longer in existence and whose liabilities Sun Pharma and Ranbaxy have assumed.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections